baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BVT Knock-Out GNMSF/ DE000VU0H1X1 /

2024-05-21 8:04:37 PM	Chg.+0.480	Bid9:59:46 PM	Ask9:59:46 PM	Underlying	Strike price	Expiration date	Option type
31.930EUR	+1.53%	- Bid Size: -	- Ask Size: -	Genmab A/S	4,402.21 DKK	2078-12-31	Put

GlobeNewswire 05-21 Genmab Completes Acquisition of ProfoundBio

GlobeNewswire 05-21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 05-17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

GlobeNewswire 05-14 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...

GlobeNewswire 05-14 Immatics Announces First Quarter 2024 Financial Results and Business Update

GlobeNewswire 05-06 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 05-02 Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire 04-30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...

GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 04-07 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...

GlobeNewswire 04-03 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

GlobeNewswire 03-20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

GlobeNewswire 03-20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

GlobeNewswire 03-11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...

GlobeNewswire 03-07 BioNTech Announces Planned Retirement of Sean Marett

GlobeNewswire 03-06 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...

GlobeNewswire 03-04 Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...

GlobeNewswire 02-14 Genmab Announces Initiation of Share Buy-Back Program

GlobeNewswire 02-14 Genmab Publishes 2023 Annual Report

GlobeNewswire 02-08 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...

GlobeNewswire 01-31 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...

GlobeNewswire 01-22 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...

GlobeNewswire 01-09 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-12-21 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...

BVT Knock-Out GNMSF/ DE000VU0H1X1 /

If you wish to receive reply to your feedback, please provide your email address.